Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Metrics to compare | 9606 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship9606PeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.7x | −36.8x | −0.7x | |
PEG Ratio | - | −0.15 | 0.00 | |
Price/Book | 9.4x | 5.9x | 2.6x | |
Price / LTM Sales | 12.6x | 18.7x | 3.4x | |
Upside (Analyst Target) | 43.5% | 38.5% | 38.2% | |
Fair Value Upside | Unlock | −12.9% | 4.7% | Unlock |